Showing 1841-1850 of 7169 results for "".
DermWireTV: Inclusion in Derm; Amgen, Incyte, Janssen, Dermavant Updates; Klisyri Launch; More
https://practicaldermatology.com/topics/practice-management/dermwiretv-inclusion-in-derm-amgen-incyte-janssen-dermavant-updates-klisyri-launch-more/19901/For an article in Pediatric Dermatology, Linda Oyesiku, MPH, a student member of the Society for Pediatric Dermatology, describes historical obstacles to inclusion and highlights opportunities to expand representation and reduce bias in dermatology. Research conducted by The Martec Group using theirTrends in the Medical Aesthetic Market
https://practicaldermatology.com/series/c-suite-chats/trends-in-the-medical-aesthetic-market/24560/Ethan Min, CEO of Benev, discusses trends in the medical aesthetic market, including the potential impact that Glucagon-like peptide-1 (GLP-1) for weight loss will have on the aesthetics industry.What Should Dermatology PAs Look For in a Contract
https://practicaldermatology.com/series/pa-perspectives/what-should-dermatology-pas-look-contract/24164/In this video, Andrew Mastro, MS, PA-C, a board-certified physician assistant (PA) at the Illinois Dermatology Institute in Chicago, shares insights into what dermatology PAs should think about for their employment contracts (particularly when starting out at their first practice). Some of the topicFirst, Do No Harm
https://practicaldermatology.com/conferences/scale-2023/first-do-no-harm/20206/Joel L. Cohen, MD, and Mathew M. Avram, MD, JD, discuss why dermatologists should report any side effects to the FDA’s Manufacturer and User Facility Device Experience (MAUDE) database.Lidocaine Shortage Update
https://practicaldermatology.com/conferences/scale-2023/lidocaine-shortage-update/20196/The current lidocaine and lidocaine with epinephrine shortage is affecting practices across the country. Joel L. Cohen, MD, and George Hruza, MD, weigh in on the shortage and potential solutions and how to minimize toxicity risks when mixing and matching different anesthetics.Scientifically Speaking: Investing in Innovation with Humberto Antunes
https://practicaldermatology.com/series/scientifically-speaking/scientifically-speaking-investing-in-innovation-with-humberto-antunes/20128/With decades of experience in dermatology and aesthetics, Humberto Antunes has helped to identify some key innovations in the field. Now part of Gore Range Capital, he continues to look for the next game-changer. He discusses his experience and shares insights on the specialties with host Joel L. CoTolerability of JAK Inhibitors Used in Dermatology
https://practicaldermatology.com/series/jak-inhibitors-in-practice/tolerability-of-jak-inhibitors-used-in-dermatology/20126/Although safety and tolerability are often intertwined, they are distinct considerations. Topical and oral JAKs used in dermatology today seem to offer good tolerability. Adelaide A. Hebert, MD and Matthew Zirwas, MD discuss potential side effects, management, and monitoring in pediatric and adult pImplications of the Overlap Between CSU and Atopic Dermatitis
https://practicaldermatology.com/programs/practical-dermatology-type-ii-inflammation-journal-club/implications-of-the-overlap-between-csu-and-atopic-dermatitis/50850/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, is joined by Northwestern University Feinberg School of Medicine Associate Professor Walter Liszewski, MD, to discuss the article “Co-existence of chronic spontaneous urticaria and atopic dermatitis: clinical and immunological perspecWhat Should Dermatology PAs Know About Training and Onboarding
https://practicaldermatology.com/series/pa-perspectives/what-should-dermatology-pas-know-about-training-and-onboarding/24395/In this video, Andrew Mastro, MS, PA-C, a board-certified physician assistant (PA) at the Illinois Dermatology Institute in Chicago, discusses what realistic expectations PAs should have while training and onboarding in a new practice. Topics include what new PAs should expect at 30, 60, and 90 daysClinical Conversations: Risks vs Benefits of JAK Inhibitors
https://practicaldermatology.com/series/jak-inhibitors-in-practice/clinical-conversations-risks-vs-benefits-of-jak-inhibitors/20108/Clinical data for JAK inhibitors show clear benefits for many patients. But these drugs are associated with certain risks and class warnings. Matt Zirwas, MD and Adelaide Hebert, MD describe how they weigh risks, educate patients, and optimize long-term management.